The former FDA Commissioner Dr. Andrew von Eschenbach has made bold statements in the past, and it once again publically stating his recommendations for the Agency. Previously he argued that efficacy should be removed from the initial FDA approval process, so FDA can focus solely on safety.  He believed this would help medical device manufacturers introduce products to market faster and provide quicker access to patients on novel therapies.